These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 26367811)

  • 21. Antibody persistence and booster response of a quadrivalent meningococcal conjugate vaccine in adolescents.
    Baxter R; Reisinger K; Block SL; Izu A; Odrljin T; Dull P
    J Pediatr; 2014 Jun; 164(6):1409-15.e4. PubMed ID: 24657122
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Neisseria meningitidis: new vaccines and preventive strategies].
    Morciano L; Zaratti L; Franco E
    Ig Sanita Pubbl; 2012; 68(1):97-104. PubMed ID: 22507995
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Development of new vaccines against meningococcal disease.
    Bröker M
    Arzneimittelforschung; 2003; 53(12):805-13. PubMed ID: 14732960
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The immune response to the capsular polysaccharide of Neisseria meningitidis group B.
    Romero JD; Outschoorn IM
    Zentralbl Bakteriol; 1997 Feb; 285(3):331-40. PubMed ID: 9084108
    [No Abstract]   [Full Text] [Related]  

  • 25. Investigation of serum bactericidal activity in childhood and adolescence 3-6 years after vaccination with a single dose of serogroup C meningococcal conjugate vaccine.
    Sakou II; Tzanakaki G; Tsolia MN; Sioumala M; Barbouni A; Kyprianou M; Papaevangelou V; Tsitsika A; Blackwell CC; Kafetzis D; Kremastinou J
    Vaccine; 2009 Jul; 27(33):4408-11. PubMed ID: 19500554
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Immunogenicity of meningococcal polysaccharide ACWY vaccine in primary immunized or revaccinated adults.
    Ferlito C; Biselli R; Cattaruzza MS; Teloni R; Mariotti S; Tomao E; Salerno G; Peragallo MS; Lulli P; Caporuscio S; Autore A; Bizzarro G; Germano V; Biondo MI; Picchianti Diamanti A; Salemi S; Nisini R; D'Amelio R
    Clin Exp Immunol; 2018 Dec; 194(3):361-370. PubMed ID: 30099753
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Neisseria: recent advances and future challenges.
    Criss AK; Tang C
    Pathog Dis; 2017 Nov; 75(8):. PubMed ID: 28957453
    [No Abstract]   [Full Text] [Related]  

  • 28. Immunologic memory with no detectable bactericidal antibody response to a first dose of meningococcal serogroup C conjugate vaccine at four years.
    McVernon J; MacLennan J; Pollard AJ; Oster P; Wakefield MJ; Danzig L; Moxon ER
    Pediatr Infect Dis J; 2003 Jul; 22(7):659-61. PubMed ID: 12886896
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Potential of the adhesin complex protein of Neisseria meningitidis for next-generation meningococcal vaccines.
    Hung MC; Heckels JE; Christodoulides M
    Expert Rev Vaccines; 2013 Sep; 12(9):981-4. PubMed ID: 24053391
    [No Abstract]   [Full Text] [Related]  

  • 30. Construction of Opa-positive and Opa-negative strains of Neisseria meningitidis to evaluate a novel meningococcal vaccine.
    Sadarangani M; Hoe JC; Callaghan MJ; Jones C; Chan H; Makepeace K; Daniels-Treffandier H; Deadman ME; Bayliss C; Feavers I; van der Ley P; Pollard AJ
    PLoS One; 2012; 7(12):e51045. PubMed ID: 23251421
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Quadrivalent meningococcal vaccines: hyporesponsiveness as an important consideration when choosing between the use of conjugate vaccine or polysaccharide vaccine.
    Bröker M; Veitch K
    Travel Med Infect Dis; 2010 Jan; 8(1):47-50. PubMed ID: 20188306
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Recognition of Neisseria meningitidis by the long pentraxin PTX3 and its role as an endogenous adjuvant.
    Bottazzi B; Santini L; Savino S; Giuliani MM; Dueñas Díez AI; Mancuso G; Beninati C; Sironi M; Valentino S; Deban L; Garlanda C; Teti G; Pizza M; Rappuoli R; Mantovani A
    PLoS One; 2015; 10(3):e0120807. PubMed ID: 25786110
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The Diversity of Meningococcal Carriage Across the African Meningitis Belt and the Impact of Vaccination With a Group A Meningococcal Conjugate Vaccine.
    MenAfriCar consortium
    J Infect Dis; 2015 Oct; 212(8):1298-307. PubMed ID: 25858956
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Vaccine offers meningitis hope.
    Butler D
    Nature; 2010 Nov; 468(7321):143. PubMed ID: 21068797
    [No Abstract]   [Full Text] [Related]  

  • 35. Meningococcal Disease in US Military Personnel before and after Adoption of Conjugate Vaccine.
    Decker MD
    Emerg Infect Dis; 2016 Nov; 22(11):2027-2028. PubMed ID: 27767923
    [No Abstract]   [Full Text] [Related]  

  • 36. Evaluation of truncated NhhA protein as a candidate meningococcal vaccine antigen.
    Peak IR; Srikhanta YN; Weynants VE; Feron C; Poolman JT; Jennings MP
    PLoS One; 2013; 8(9):e72003. PubMed ID: 24039731
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Emergence of serogroup X meningococcal disease in Africa: need for a vaccine.
    Xie O; Pollard AJ; Mueller JE; Norheim G
    Vaccine; 2013 Jun; 31(27):2852-61. PubMed ID: 23623866
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effectiveness of BC meningococcal vaccine in Brazil.
    Nishioka S
    Int J Epidemiol; 1996 Oct; 25(5):1102-3. PubMed ID: 8921501
    [No Abstract]   [Full Text] [Related]  

  • 39. [New vaccines against group B meningococcal diseases].
    Hietalahti J; Meri S
    Duodecim; 2015; 131(6):525-32. PubMed ID: 26237895
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Bactericidal antibody response to Neisseria meningitidis serogroup B in patients with bacterial meningitis: effect of immunization with an outer membrane protein vaccine.
    Milagres LG; Gorla MC; Rebelo MC; Barroso DE
    FEMS Immunol Med Microbiol; 2000 Aug; 28(4):319-27. PubMed ID: 10891656
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.